Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Thymus Transplantation With Immunosuppression #950

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Thymus Transplantation Inclusion:~* Must have 1 of following: 22q11 or 10p13 hemizygosity; hypocalcemia requiring replacement; congenital heart defect; CHARGE association or CHD7 mutation; or abnormal ears plus mother w/diabetes (type I, type II, gestational).~* \<50 CD3+ T cells/cumm or \<50 CD3+ T cells/cumm that are CD62L+ CD45RA+ (cluster of differentiation 45RA) (naïve phenotype), or \<5% of CD3+ count being CD62L+ CD45RA+~Atypical DiGeorge:~* Must have, or have had, a rash. If rash present, rash biopsy must show T cells in skin. If rash \& adenopathy resolved, must have \>50/cumm T cells \& naive T cell must be \<50/cumm or \<5% of T cells.~Typical DiGeorge:~* CD3+ CD45RA+ CD62L+ T cells \<50/mm3 or \<5% of total T cells~Parathyroid Transplantation Additional Inclusion:~* 2 studies in recipient which PTH\<5 pg/ml when ionized calcium \<1.1 mmol/L. Can be done anytime pre-tx; 1 must be done while at Duke Hospital.~* Parent(s) willing \& eligible to be donors~Thymus Transplantation Exclusion:~* Heart surgery \<4 wks pre-tx~* Heart surgery anticipated w/in 3 months after proposed tx~* Rejection by surgeon or anesthesiologist as surgical candidate~* Lack of sufficient muscle tissue to accept transplant of 4 grams/m2 BSA~* HIV infection~* Prior attempts at immune reconstitution, such as bone marrow tx or previous thymus tx~* CMV(\>500 copies/ml blood by PCR on 2 tests)~* Ventilator dependence~Parathyroid Donor Inclusion:~* \>18 years of age~* Serum calcium in normal range~* Normal PTH function~* HLA typing consistent with parentage~* Not on anticoagulation or can come off~* Parent chosen will share HLA-DR allele with thymus donor that was not inherited by the recipient. If no HLA matching at all, then either parent is acceptable if the parent meets other criteria.~Parathyroid Donor Exclusion:~* \<18 years old~* Hypoparathyroidism-low PTH in presence of low serum calcium \& high serum phosphate~* Hyperparathyroidism(or history)-elevated PTH in presence of high serum calcium and low serum phosphate.~* History of cancer~* Donor only living involved parent/guardian of recipient~* Evidence of HIV-1, HIV-2, HTLV-1, HTLV-2, syphilis, hepatitis B, hepatitis C, West Nile virus, or Chagas disease~* Creutzfeldt Jakob disease (CJD)~* Elevated liver function studies: AST, ALT, alkaline phosphatase \>3x upper normal limit~* Receipt of xenograft or risk factors for SARS, CJD and/or smallpox exposure. {If CJD risk factors but not active disease, parent may give permission for parathyroid use.}~* Urine CMV positive~* Positive CMV IgM~* Positive IgM anti-EBV VCA~* On blood thinners and cannot stop for parathyroid donation~* Elevated PT or PTT (\>ULN)~* Platelets\<100,000~* Positive Toxoplasma IgM~* Donor will receive a history and physical; may be excluded based on PI's medical judgment.~* Hemoglobin \<9g/dl~* Infectious head or neck lesion~* Goiter on ultrasound~* Abnormal fiberoptic laryngoscopy of vocal cords~* HLA inconsistent with parentage~* Pregnancy~* Positive HSV IgG isn't exclusion; post-tx prophylaxis needed for recipient if donor is HSV IgG+.~* Positive VZV IgG isn't exclusion; post-tx prophylaxis needed if donor is VZV IgG+.~* Medical concern of independent otolaryngologist.~* Concern by medical psychologist/social worker that potential donor isn't competent or does not understand risks.~* Questionnaire responses can lead to exclusion.~Mother of DiGeorge Inclusion:~• Provides consent to use blood/buccal sample. No exclusions except unwillingness to consent; or, provide blood/buccal sample.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression (Type: EXPERIMENTAL): Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
- CTTI with Parathyroid Transplantation w/immunosuppression (Type: EXPERIMENTAL): Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).